Skip to main content
Clinical Trials/NCT03321201
NCT03321201RecruitingNot Applicable

Cauterization Versus fibrin Glue for Conjunctival Autografting in Primary Pterygium Surgery

University of Split, School of Medicine2 sites in 1 country164 target enrollmentStarted: May 8, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
164
Locations
2
Primary Endpoint
Recurrence of pterygium

Study Overview

Brief Summary

Pterygium is a noncancerous growth of the conjunctival tissue over the cornea. It is a progressive disease that may lead to visual impairment in advanced stages, as well as restriction of ocular motility, chronic inflammation and cosmetic concerns. Surgical removal is the treatment of choice, but recurrence of pterygium is a frequent problem. In this randomized controlled cauterization will be compared with fibrin glue for conjunctival autografting in primary pterygium surgery.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Masking Description

Surgeons will not be blinded. All the other investigators, as well as study participants, outcome assessors and author that will analyze the data will be blinded.

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • adults (older than 18 years of age)
  • both sexes
  • primary nasal pterygia ˃4 mm, which tends to increase, including patients with reduced visual acuity, chronic inflammation, cosmetic reasons
  • if the patients had a bilateral pterygium, only one eye will be operated

Exclusion Criteria

  • connective tissue disease
  • prior eye surgery
  • chronic use of topical drugs (anti-glaucoma drugs)

Outcomes

Primary Outcomes

Recurrence of pterygium

Time Frame: 180 days

Any re-growth of tissue from the area of excision across the limbus onto the cornea.

Secondary Outcomes

  • Pterygium-induced astigmatism(7, 30 and 180 days)
  • Ocular surface condition(7, 30 and 180 days)
  • Pain(7, 30 and 180 days)
  • Complication rate(7, 30 and 180 days)
  • Postoperative discomfort, tearing, pain and foreign body sensation(7, 30 and 180 days)
  • Surgical time(During the surgery)
  • Economic Analysis(180 days)
  • Flap time(During the surgery)

Investigators

Sponsor
University of Split, School of Medicine
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Livia Puljak

Associate Professor

University of Split, School of Medicine

Study Sites (2)

Loading locations...

Similar Trials

Cauterization Versus fibrin Glue for... | Clinical Trial